(33R,35S,91R,92R,5S)-5-(叔丁基)-17-甲氧基-4,7-二氧基-2,8-二氧基-6-氮杂-1(2,3)-喹恶啉-3(3,1)-吡咯烷-9(1,2)-环丙烷环己基-35-羧酸结构式
|
常用名 | (33R,35S,91R,92R,5S)-5-(叔丁基)-17-甲氧基-4,7-二氧基-2,8-二氧基-6-氮杂-1(2,3)-喹恶啉-3(3,1)-吡咯烷-9(1,2)-环丙烷环己基-35-羧酸 | 英文名 | MK-5172 |
---|---|---|---|---|
CAS号 | 1206524-85-7 | 分子量 | 554.635 | |
密度 | 1.3±0.1 g/cm3 | 沸点 | 825.0±65.0 °C at 760 mmHg | |
分子式 | C29H38N4O7 | 熔点 | N/A | |
MSDS | N/A | 闪点 | 452.7±34.3 °C |
用途MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. |
中文名 | (33R,35S,91R,92R,5S)-5-(叔丁基)-17-甲氧基-4,7-二氧基-2,8-二氧基-6-氮杂-1(2,3)-喹恶啉-3(3,1)-吡咯烷-9(1,2)-环丙烷环己基-35-羧酸 |
---|---|
英文名 | (1aR,5S,8S,10R,22aR)-5-tert-butyl-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid |
英文别名 | 更多 |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 825.0±65.0 °C at 760 mmHg |
分子式 | C29H38N4O7 |
分子量 | 554.635 |
闪点 | 452.7±34.3 °C |
精确质量 | 554.274048 |
PSA | 143.67000 |
LogP | 4.64 |
蒸汽压 | 0.0±3.1 mmHg at 25°C |
折射率 | 1.616 |
储存条件 | -20°C,干燥密封 |
S1492_Selleck |
(1R,18R,20R,24S,27S)-7-Methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.0.0.0]nonacosa-3,5,7,9,11-pentaene-27-carboxylic acid |
8H-7,10-Methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid, 5-(1,1-dimethylethyl)-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-14-methoxy-3,6-dioxo-, (1aS,5S,8S,10R,22aR)- |
8H-7,10-Methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxylic acid, 5-(1,1-dimethylethyl)-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-14-methoxy-3,6-dioxo-, (1aR,5S,8S,10R,22aR)- |
(1R,18R,20S,24S,27S)-7-Methoxy-24-(2-methyl-2-propanyl)-22,25-dioxo-2,21-dioxa-4,11,23,26-tetraazapentacyclo[24.2.1.0.0.0]nonacosa-3,5(10),6,8,11-pentaene-27-carboxylic acid |
UNII-RU4QU6O6X6 |
MK-5172 |
Grazoprevir |